Skip to content
Search AI Powered

Latest Stories

Will My Insurance Cover Psychedelic-Assisted Therapy? 

Key Takeaways:
- The American Medical Association (AMA) recently approved insurance billing codes for psychedelic therapy.
- The approval does not mean insurance companies will provide coverage for psychedelic therapy.
- DEA de-scheduling coupled with Food and Drug Administration (FDA) approval of psychedelics will be key for insurance companies to consider reimbursement.

Will Insurance Cover Psychedelic-Assisted Therapy?
Will Insurance Cover Psychedelic-Assisted Therapy?

The American Medical Association (AMA) has taken a significant step forward for psychedelic therapy by approving Current Procedural Technology (CPT) III codes for these treatments. The move has sparked hope among advocates and experts that insurance coverage for psychedelic-assisted therapy is on the horizon. However, this approval is only one piece of the puzzle, and there are several hurdles to overcome before insurance providers will consider reimbursing patients for these treatments.

CPT codes are essential in the healthcare industry as they allow healthcare providers to track and bill for various procedures and services. The newly approved CPT III codes for psychedelic therapies will become effective in January 2024. 


However, it is crucial to note that these codes do not equal coverage. On its website, the AMA states that the “inclusion of a descriptor and its associated code number does not represent endorsement by the AMA of any particular diagnostic or therapeutic procedure or service. Inclusion or exclusion of a procedure or service does not imply any health insurance coverage or reimbursement policy.”

Enthea, is one of the first providers of insurance plans for psychedelic healthcare, with plans that currently cover ketamine-assisted therapy; MDMA- and psilocybin-assisted therapies will be added as they become FDA-approved in the next several years.

“Through the creation of the country’s first psychedelic healthcare provider network, Enthea is taking a big step in creating access to these new, evidence-based healing options,” said Sherry Rais, CEO and Co-Founder of Enthea. “And as a workplace benefit, this treatment becomes affordable. Next year, most employers across the U.S will be able to offer these innovative treatments, covered under insurance, for the first time.”

Ms. Rais also acknowledges that most traditional insurance providers will likely require more concrete evidence before committing to reimbursement.

The legal status of psychedelics plays a crucial role in insurance coverage decisions. While some states have legalized or decriminalized certain psychedelic substances for specific mental health conditions, the Food and Drug Administration (FDA) has not yet approved psychedelics for therapeutic use. FDA approval, along with DEA rescheduling, is vital for insurance companies to consider covering psychedelic therapy.

Several companies and organizations, including COMPASS Pathways, MAPS Public Benefit Corporation, and Numinus, are actively working to pave the way for potential insurance coverage of MDMA and psilocybin. Despite the progress, there are still significant costs associated with psychedelic therapy. 

The substances themselves are not expensive, but the long-term talk therapy needed after a psychedelic-assisted session can be costly. Integration, the process of incorporating insights from the psychedelic experience into daily life, involves activities like journaling, mindfulness practices, and continuing talk therapy.

Insurance coverage not only reduces financial burdens for patients but also provides reassurance about the safety and viability of psychedelic therapy. According to Payton Nyquvest, CEO of Numinus, insurance coverage will be essential for increasing access to these treatments. It will also encourage more people to consider psychedelic therapy as a viable option for mental health care.

The University of California Berkeley Center for the Science of Psychedelics conducted a survey revealing that more than half of respondents support FDA approval of psychedelics. However, insurance coverage for psychedelic therapy is not yet widespread. Even FDA-approved treatments like ketamine, a Schedule III controlled substance, are not consistently covered by insurance companies.

The process of integrating psychedelic-assisted therapy into the mainstream healthcare system is in its early stages. The American Psychedelic Practitioners Association (APPA) is working on accrediting practitioners in the field to ensure legitimacy and safety. However, it will take time and effort to gain acceptance and certification in the clinical world.

While the approval of CPT codes is a positive step forward, there is still a long road ahead before insurance coverage for psychedelic-assisted therapy becomes a reality. Full FDA approval and DEA rescheduling are paramount, along with peer-reviewed evidence from clinical trials and proper practitioner training. Insurance companies will need convincing data on safety, efficacy, and cost-effectiveness before providing comprehensive coverage for these groundbreaking treatments.

As the field of psychedelic therapy continues to evolve, patients, providers, and advocates remain hopeful that insurance coverage will eventually be available, making these transformative treatments more accessible to those in need. However, until the necessary steps are taken, patients will need to explore alternative financing options to access this potentially life-changing therapy.

More For You

11 Movies to Watch While Tripping on Your Next Shroom Trip

11 Movies to Watch While Tripping on Your Next Shroom Trip

Many activities are amplified for the better when you're tripping on magic mushrooms, and watching trippy movies is definitely near the top of that list.

Shrooms provide consumers with an almost otherworldly experience: one where colors are brighter, music is magical, and everything is open to a seemingly unprecedented interpretation.

Keep ReadingShow less
Why is Golden Teacher so popular?
Why is Golden Teacher so popular?

Golden Teacher Mushrooms: Everything You Need to Know

Golden Teacher mushrooms (GT Mushrooms) are one of the most popular strains of psilocybin mushrooms. They are mostly cultivated for their above-average psilocybin potency, which serves as a beginner's gateway to psychedelic mushrooms. They feature caramel-colored stems and caps speckled with yellow hence the name Golden Teacher. 

These psychedelic mushroom strains are also known as golden caps, boomers, goldies, caps, and cubies. While the information on their origin is quite unknown or undocumented, anecdotal reference shows that the golden teacher mushrooms were first reported in a scientific literature in 1906 in Cuba, while research on the strains is most likely to have started in the early eighties. 

Keep ReadingShow less
Magic mushrooms taste gross. Let's fix that.
Magic mushrooms taste gross. Let's fix that.

6 Ways to Consume Magic Mushrooms (that don't involve a peanut butter sandwich)

If you have ever consumed magic mushrooms or truffles, then you know they don’t always have the most pleasant taste, in fact, some of them are like eating a mouthful of dirt.  

However, with the recent rise of popularity through legalization, decriminalization, and the public becoming more aware of the benefits and potential good that comes with these psilocybin-packed fungi, we see why people may overlook the flavor.

Keep ReadingShow less
Ranking Magic Mushrooms by Potency
Ranking Magic Mushrooms by Potency
Tripsitter

Shroom Showdown: Ranking Magic Mushrooms by Potency

From  Psilocybe azurescens to Psilocybe cubensis   — the potency of magic mushrooms varies greatly.

A single gram of one species is enough to shift reality on its axis — the same amount of another may be barely perceptible.

Keep ReadingShow less
Magic mushroom spores are actually legal in most places.
Magic mushroom spores are actually legal in most places.

Psilocybin 101: Your Guide to Magic Mushroom Spores

Why are more people interested in magic mushrooms?

Magic mushrooms belong to a class of intoxicating mushrooms known as psychedelic mushrooms. They contain a combination of psilocybin, psilocin, and baeocystin, which are intoxicating. These compounds can interact with the serotonin receptors to promote relaxation with a feeling of euphoria. Recent clinical trials have shown their possible use for mental disorders, depression, and addiction. 

The practice and use of magic mushrooms started over 6000 years ago. At that time, people heavily relied on its psychotropic (mind-altering) properties to communicate with the divine and trigger trips. It was an important part of several religious rituals and was often utilized for its therapeutic benefits. 

Keep ReadingShow less